Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9235569 | 1.00 | NPC1 (0.44) | NPC1RAB9AL3MBTL1MTNR1AMTNR1B | |
| SCHEMBL13429569 | 0.88 | SYK (0.50) | NPC1RAB9AL3MBTL1PTGDR2HTR2C | |
| SCHEMBL4430164 | 0.84 | MTNR1A (0.46) | MTNR1AMTNR1BACE | |
| SCHEMBL9964898 | 0.84 | NPC1 (0.48) | NPC1RAB9AL3MBTL1PTGDR2HTR2C | |
| SCHEMBL9747326 | 0.84 | NPC1 (0.48) | NPC1RAB9AL3MBTL1PTGDR2HTR2C | |
| SCHEMBL8272822 | 0.82 | NPC1 (0.51) | NPC1RAB9AL3MBTL1PTGDR2HTR2C | |
| SCHEMBL9750210 | 0.81 | NPC1 (0.50) | NPC1RAB9AL3MBTL1PTGDR2HTR2C | |
| SCHEMBL9964901 | 0.78 | NPC1 (0.47) | NPC1RAB9AL3MBTL1PTGDR2HTR2C | |
| SCHEMBL9092066 | 0.78 | NPC1 (0.47) | NPC1RAB9AL3MBTL1PTGDR2HTR2C | |
| SCHEMBL5764293 | 0.77 | DRD2 (0.53) | NPC1RAB9AL3MBTL1ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | CSO of MicuRx Pharmaceuticals, Inc. | 2012-06-21 | — | — | US | disclosed |
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | CSO of MicuRx Pharmaceuticals, Inc. | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | NISCH, NOD1, NQO1 | NPC1 515/4885RAB9A 1343/4885L3MBTL1 3076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.